News
FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include adults aged 18 to 59 who are at high risk of severe illness if they contract respiratory syncytial virus. Previously the vaccine, sold under the name mResvia, was only licensed for use in adults aged 60 and older.
THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...
The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...
Merck & Co. said it won US approval for a shot that protects against RSV, the most common cause of hospitalization among ...
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.
Queensland’s Chief Health Officer has praised the new immunisation program that has protected hundreds of Queensland babies from Respiratory Syncytial Virus (RSV), as flu and Covid-19 cases spike ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback